Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Cumulative Phase 2 clinical trials (trials): 45.00 trials in FY2025, up 15.4% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
45.00
Period ended Dec 31, 2025
Change on a year earlier
+15.4%
39.00 in FY2024
History
8 years
Since FY2018
Sources
1
ClinicalTrials.gov API v2 (ModernaTX, Inc.)
Where the FY2025 figure comes from
Source: ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Reported in ClinicalTrials.gov API v2 (ModernaTX, Inc.).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cumulative Phase 2 clinical trials (trials) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45.00 | +15.4% | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
| FY2024 | Dec 31, 2024 | 39.00 | +14.7% | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
| FY2023 | Dec 31, 2023 | 34.00 | +47.8% | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
| FY2022 | Dec 31, 2022 | 23.00 | +76.9% | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
| FY2021 | Dec 31, 2021 | 13.00 | +160.0% | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
| FY2020 | Dec 31, 2020 | 5.00 | +66.7% | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
| FY2019 | Dec 31, 2019 | 3.00 | +200.0% | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
| FY2018 | Dec 31, 2018 | 1.00 | – | ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗ |
Cite this data
StockData. (2026). Moderna Cumulative Phase 2 clinical trials (trials), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ctgov-cum-phase2
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.